Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

Background/Aim Type 1 diabetes is an autoimmune disease that involves the development of autoantibodies against pancreatic islet beta‐cell antigens, preceding clinical diagnosis by a period of preclinical disease activity. As screening activity to identify autoantibody‐positive individuals increases...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Diabetes/metabolism research and reviews Ročník 40; číslo 2; s. e3777 - n/a
Hlavní autoři:	Hendriks, A. Emile J., Marcovecchio, M. Loredana, Besser, Rachel E. J., Bonifacio, Ezio, Casteels, Kristina, Elding Larsson, Helena, Gemulla, Gita, Lundgren, Markus, Kordonouri, Olga, Mallone, Roberto, Pociot, Flemming, Szypowska, Agnieszka, Toppari, Jorma, Ziegler, Anette G., Mathieu, Chantal, Achenbach, Peter, Mathieu, C., Gillard, P., Casteels, K., Overbergh, L., Wallace, C., Evans, M., Thankamony, A., Hendriks, A. E. J., Bruggraber, S., Marcovecchio, M. L., Peakman, M., Tree, T., Richardson, S., Todd, J., Wicker, L., Mander, A., Dayan, C., Alhadj Ali, M., Pieber, T., Eizirik, D., Cnop, M., Brunak, S., Pociot, F., Johannesen, J., Rossing, P., Legido Quigley, C., Mallone, R., Scharfmann, R., Boitard, C., Knip, M., Otonkoski, T., Lahesmaa, R., Oresic, M., Toppari, J., Danne, T., Ziegler, A. G., Achenbach, P., Rodriguez‐Calvo, T., Solimena, M., Bonifacio, E., Speier, S., Holl, R., Dotta, F., Chiarelli, F., Marchetti, P., Bosi, E., Cianfarani, S., Ciampalini, P., Beaufort, C., Dahl‐Jørgensen, K., Skrivarhaug, T., Krogvold, L., Jarosz‐Chobot, P., Battelino, T., Thorens, B., Roep, B., Nikolic, T., Zaldumbide, A., Lernmark, A., Costecalde, G., Strube, T., Schulte, A., Nitsche, A., Vela, J., Herrath, M., Wesley, J., Napolitano‐Rosen, A., Thomas, M., Schloot, N., Goldfine, A., Waldron‐Lynch, F., Kompa, J., Vedala, A., Hartmann, N., Nicolas, G., Rampelbergh, J., Bovy, N., Dutta, S., Soderberg, J., Ahmed, S., Martin, F., Latres, E., Koralova, A.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Wiley Subscription Services, Inc 01.02.2024
Témata:	Antigens Autoantibodies Autoimmune diseases Clinical Medicine Diabetes Diabetes mellitus (insulin dependent) Diagnosis Endocrinology and Diabetes Endokrinologi och diabetes Glucose monitoring Ketoacidosis Klinisk medicin Medical and Health Sciences Medicin och hälsovetenskap monitoring presymptomatic type 1 diabetes Primary care screening specialist care staging presymptomatic type 1 diabetes primary care specialist care screening monitoring staging
ISSN:	1520-7552, 1520-7560, 1520-7560
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Background/Aim Type 1 diabetes is an autoimmune disease that involves the development of autoantibodies against pancreatic islet beta‐cell antigens, preceding clinical diagnosis by a period of preclinical disease activity. As screening activity to identify autoantibody‐positive individuals increases, a rise in presymptomatic type 1 diabetes individuals seeking medical attention is expected. Current guidance on how to monitor these individuals in a safe but minimally invasive way is limited. This article aims to provide clinical guidance for monitoring individuals with presymptomatic type 1 diabetes to reduce the risk of diabetic ketoacidosis (DKA) at diagnosis. Methods Expert consensus was obtained from members of the Fr1da, GPPAD, and INNODIA consortia, three European diabetes research groups. The guidance covers both specialist and primary care follow‐up strategies. Results The guidance outlines recommended monitoring approaches based on age, disease stage and clinical setting. Individuals with presymptomatic type 1 diabetes are best followed up in specialist care. For stage 1, biannual assessments of random plasma glucose and HbA1c are suggested for children, while annual assessments are recommended for adolescents and adults. For stage 2, 3‐monthly clinic visits with additional home monitoring are advised. The value of repeat OGTT in stage 1 and the use of continuous glucose monitoring in stage 2 are discussed. Primary care is encouraged to monitor individuals who decline specialist care, following the guidance presented. Conclusions As type 1 diabetes screening programs become more prevalent, effective monitoring strategies are essential to mitigate the risk of complications such as DKA. This guidance serves as a valuable resource for clinicians, providing practical recommendations tailored to an individual's age and disease stage, both within specialist and primary care settings.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	1520-7552 1520-7560 1520-7560
DOI:	10.1002/dmrr.3777